Maggie L. Shaw

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how enhancements to telemedicine precipitated by the COVID-19 pandemic have made lasting and meaningful changes to oncology care, including that these care improvements will persist post pandemic.

Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.

The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.

Hope S. Rugo, MD, FASCO, is professor of medicine and the director of the Breast Oncology and Clinical Trials Education program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. She discusses her experience with palbociclib and letrozole in advanced breast cancer.

The new trial was the first to investigate outcomes among a patient population living with HIV (PLWH) who were treated for anal precancerous growths, or high-grade squamous intraepithelial lesions.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, address the impact of effective treatments of chronic cough on patient quality of life (QOL).

Amanda Ely is CEO of the Children’s HIV Association (CHIVA), an organization that provides support to children living with HIV in the United Kingdom and Ireland and their families.

This new study, which the authors claim is the first to do so, investigated the relationship between COVID-19 vaccination status and survival outcomes among individuals with heart failure.

Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).

Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.

Thanos Zomas, MD, global medical lead, Lymphoma and Leukemia, and global medical lead, Adcetris Program, at Takeda Oncology discusses updated results from the ECHELON-1 study.

David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.

Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).

Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

This new study, from Taiwan, investigated how menopause affects ventricular structure and function and its possible impact on heart failure among women.

Will Nutland, DrPH, is cofounder of PrEPster, honorary assistant professor at the London School of Hygiene and Tropical Medicine, and an activist.

This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses 3 ways in which the FDA can provide, and has provided, assistance on the capture of real-word data (RWD) in electronic medical records.

Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences clinical outcomes in this population.

The authors of this study evaluated outcomes among children aged 7 to 16 years, all living with type 1 diabetes (T1D), who attended a 3-day virtual education camp that focused on their use of a closed-loop control (CLC) system for insulin delivery.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, discusses the important need for chronic cough therapies and what issues with current treatments should be addressed by next-generation medications.

This study evaluated levels of 4 biomarkers associated with heart failure with reduced ejection fraction (HFrEF) before and after treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan.

Continuous glucose monitor (CGM) use as part of a telemedicine program in patients with type 2 diabetes transitioning out of a hospital setting and to a different diabetes therapy was evaluated in this new open-label study.

Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses the medicines discovery process and how real-world data can be used to evaluate patient and tumor response to treatment regimens.

Anna Brewster, services and volunteer manager at The Food Chain, a London-based charity that provides short-term assistance to persons living with HIV (PLWH), discusses how education provided through the Eating Positively program connects the importance of food and proper nutrition to health outcomes.

Two periods of sacubitril/valsartan initiation were compared in a study population of patients with heart failure with reduced ejection fraction (HFrEF): less than 3 months or 3 or more months following first HFrEF diagnosis.

Type 1 diabetes (T1D) can be especially difficult to manage in older adults, so this new multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy.